CL2015001724A1 - Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros. - Google Patents
Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros.Info
- Publication number
- CL2015001724A1 CL2015001724A1 CL2015001724A CL2015001724A CL2015001724A1 CL 2015001724 A1 CL2015001724 A1 CL 2015001724A1 CL 2015001724 A CL2015001724 A CL 2015001724A CL 2015001724 A CL2015001724 A CL 2015001724A CL 2015001724 A1 CL2015001724 A1 CL 2015001724A1
- Authority
- CL
- Chile
- Prior art keywords
- autism
- schizophrenia
- anxiety
- peptides
- depression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12199012 | 2012-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015001724A1 true CL2015001724A1 (es) | 2015-10-16 |
Family
ID=47471593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015001724A CL2015001724A1 (es) | 2012-12-21 | 2015-06-18 | Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros. |
Country Status (34)
Country | Link |
---|---|
US (1) | US9868766B2 (es) |
EP (1) | EP2935312B1 (es) |
JP (1) | JP6067878B2 (es) |
KR (1) | KR101819804B1 (es) |
CN (1) | CN104870466B (es) |
AR (1) | AR094225A1 (es) |
AU (1) | AU2013363768B2 (es) |
BR (1) | BR112015014010A2 (es) |
CA (1) | CA2895150C (es) |
CL (1) | CL2015001724A1 (es) |
CR (1) | CR20150271A (es) |
DK (1) | DK2935312T3 (es) |
EA (1) | EA026687B1 (es) |
ES (1) | ES2690317T3 (es) |
HK (1) | HK1208477A1 (es) |
HR (1) | HRP20181569T1 (es) |
HU (1) | HUE039848T2 (es) |
IL (1) | IL239519A (es) |
LT (1) | LT2935312T (es) |
MA (1) | MA38272A1 (es) |
MX (1) | MX358684B (es) |
MY (1) | MY176398A (es) |
NZ (1) | NZ708175A (es) |
PE (1) | PE20151446A1 (es) |
PH (1) | PH12015501145B1 (es) |
PL (1) | PL2935312T3 (es) |
PT (1) | PT2935312T (es) |
RS (1) | RS57690B1 (es) |
SG (1) | SG11201504883PA (es) |
SI (1) | SI2935312T1 (es) |
TW (1) | TWI558726B (es) |
UA (1) | UA119034C2 (es) |
WO (1) | WO2014095773A1 (es) |
ZA (1) | ZA201504186B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11485753B2 (en) | 2012-12-21 | 2022-11-01 | Janssen Pharmaceutica Nv | Substituted nucleosides, nucleotides and analogs thereof |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
KR101819804B1 (ko) | 2012-12-21 | 2018-01-17 | 에프. 호프만-라 로슈 아게 | 옥시토신 작용제로서의 펩타이드 |
KR102116107B1 (ko) | 2013-12-30 | 2020-05-28 | 삼성디스플레이 주식회사 | 표시 장치 |
WO2015106200A2 (en) | 2014-01-10 | 2015-07-16 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
PE20161559A1 (es) | 2014-06-03 | 2017-01-12 | Hoffmann La Roche | Peptidos como agonistas de la oxitocina |
AP2016009605A0 (en) | 2014-06-17 | 2016-12-31 | Pfizer | Substituted dihydroisoquinolinone compounds |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
TR201815872T4 (tr) * | 2014-08-07 | 2018-11-21 | Hoffmann La Roche | Oksitosin analoglarının hazırlanması için prosesler. |
WO2016028571A2 (en) * | 2014-08-18 | 2016-02-25 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
US10441627B2 (en) | 2014-09-19 | 2019-10-15 | Ferring B.V. | Method of treating prader-willi syndrome |
EP3362754B1 (en) | 2015-10-15 | 2021-12-22 | Cornell University | Proteasome inhibitors and uses thereof |
EP3694605A4 (en) | 2017-10-11 | 2021-10-27 | Cornell University | PEPTIDOMIMETIC PROTEASOME INHIBITORS |
WO2020061414A1 (en) | 2018-09-20 | 2020-03-26 | Levo Therapeutics, Inc. | Stable intranasal formulations of carbetocin |
TW202034899A (zh) | 2018-09-20 | 2020-10-01 | 克里斯托弗 S 布萊恩特 | 卡貝縮宮素藥品及其製備方法 |
WO2021126990A1 (en) * | 2019-12-16 | 2021-06-24 | The Scripps Research Institute | Oxytocin derivatives with improved properties |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8673841B2 (en) | 2008-03-31 | 2014-03-18 | Ferring B.V. | Oxytocin analogues |
TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
ES2509270T3 (es) * | 2009-10-01 | 2014-10-17 | The University Of Sydney | Terapia y prevención del alcoholismo |
KR101819804B1 (ko) | 2012-12-21 | 2018-01-17 | 에프. 호프만-라 로슈 아게 | 옥시토신 작용제로서의 펩타이드 |
-
2013
- 2013-12-17 KR KR1020157016376A patent/KR101819804B1/ko active IP Right Grant
- 2013-12-17 CN CN201380066617.7A patent/CN104870466B/zh not_active Expired - Fee Related
- 2013-12-17 WO PCT/EP2013/076783 patent/WO2014095773A1/en active Application Filing
- 2013-12-17 AU AU2013363768A patent/AU2013363768B2/en not_active Ceased
- 2013-12-17 MX MX2015007365A patent/MX358684B/es active IP Right Grant
- 2013-12-17 DK DK13814079.3T patent/DK2935312T3/en active
- 2013-12-17 PL PL13814079T patent/PL2935312T3/pl unknown
- 2013-12-17 ES ES13814079.3T patent/ES2690317T3/es active Active
- 2013-12-17 HU HUE13814079A patent/HUE039848T2/hu unknown
- 2013-12-17 RS RS20181124A patent/RS57690B1/sr unknown
- 2013-12-17 PE PE2015001058A patent/PE20151446A1/es unknown
- 2013-12-17 SI SI201331190T patent/SI2935312T1/sl unknown
- 2013-12-17 MA MA38272A patent/MA38272A1/fr unknown
- 2013-12-17 SG SG11201504883PA patent/SG11201504883PA/en unknown
- 2013-12-17 EP EP13814079.3A patent/EP2935312B1/en active Active
- 2013-12-17 JP JP2015548420A patent/JP6067878B2/ja not_active Expired - Fee Related
- 2013-12-17 BR BR112015014010A patent/BR112015014010A2/pt not_active IP Right Cessation
- 2013-12-17 CA CA2895150A patent/CA2895150C/en not_active Expired - Fee Related
- 2013-12-17 MY MYPI2015001585A patent/MY176398A/en unknown
- 2013-12-17 LT LTEP13814079.3T patent/LT2935312T/lt unknown
- 2013-12-17 UA UAA201506906A patent/UA119034C2/uk unknown
- 2013-12-17 NZ NZ708175A patent/NZ708175A/en not_active IP Right Cessation
- 2013-12-17 EA EA201591078A patent/EA026687B1/ru not_active IP Right Cessation
- 2013-12-17 PT PT13814079T patent/PT2935312T/pt unknown
- 2013-12-20 TW TW102147655A patent/TWI558726B/zh not_active IP Right Cessation
- 2013-12-20 AR ARP130104962A patent/AR094225A1/es unknown
-
2015
- 2015-05-21 CR CR20150271A patent/CR20150271A/es unknown
- 2015-05-22 PH PH12015501145A patent/PH12015501145B1/en unknown
- 2015-06-10 ZA ZA2015/04186A patent/ZA201504186B/en unknown
- 2015-06-18 US US14/743,009 patent/US9868766B2/en active Active
- 2015-06-18 CL CL2015001724A patent/CL2015001724A1/es unknown
- 2015-06-18 IL IL239519A patent/IL239519A/en active IP Right Grant
- 2015-09-18 HK HK15109189.5A patent/HK1208477A1/xx not_active IP Right Cessation
-
2018
- 2018-10-02 HR HRP20181569TT patent/HRP20181569T1/hr unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11485753B2 (en) | 2012-12-21 | 2022-11-01 | Janssen Pharmaceutica Nv | Substituted nucleosides, nucleotides and analogs thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015001724A1 (es) | Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros. | |
CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
CL2014003462A1 (es) | Uso de compuestos aminotriazolopiridinas sustituidos, en el tratamiento de afecciones inflamatorias, autoinmunitarias, proliferativas, alergias, rechazo de trasplantes, entre otras; composicion farmaceutica que los comprende; combinacion farmaceutica. | |
CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
CL2015003735A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
CL2013003019A1 (es) | Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih. | |
CL2014002334A1 (es) | Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras. | |
BR112015022625A2 (pt) | micromatrizes para entrega de agente terapêutico e métodos de uso | |
CL2014002732A1 (es) | Compuestos derivados de imidazolil-pirimidinas sustituidas con amino-indolilo, inhibidores de la proteina quinasa syk; compuestos intermediarios; formulaciones farmaceuticas que los contienen; uso en el tratamiento de enfermedades tales como asma, epoc, rinitis alergica, entre otras. | |
CL2015001802A1 (es) | Compuestos derivados de quinolonas; composicion farmaceutica; y uso para el tratamiento de enfermedaddes mediadas por la inhibicion de hif polilhidrolasa, tal como infarto al miocardio, accidente cerebrovascular, anemia, entre otros | |
CL2012002771A1 (es) | Compuestos derivados de ariletinilo sustituidos, moduladores de los receptores mglur5; proceso de obtencion; composicion farmaceutica; y su uso en el tratamiento o prevencion de la esquizofrenia, enfermedades cognitivas, sindrome de x fragil o el autismo. | |
UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
CL2016001543A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas. | |
CL2016001266A1 (es) | Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo. | |
CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
CL2014002919A1 (es) | Compuestos derivados de 1h-indol-4-il-metil-(heterociclo benzofusionado); composicion y combinacion farmaceutica; y uso en el tratamiento de un trastorno mediado por la activacion del complemento o la ruta alternativa del mismo. | |
CL2015002030A1 (es) | Dihidropirimidinomas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica | |
EP2889308A4 (en) | SUPERFAMIL ALPHA O CONOTOXIN PEPTIDE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
CL2015001318A1 (es) | Compuestos derivados de pirazina, agonistas del receptor cb2; proceso de obtencion; composicion farmaceutica y el uso en el tratamiento de enfermedades tales como aterosclerosis, glaucoma, diabetes, entre otras. |